These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37494485)

  • 21. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
    Dauvilliers Y; Bassetti C; Lammers GJ; Arnulf I; Mayer G; Rodenbeck A; Lehert P; Ding CL; Lecomte JM; Schwartz JC;
    Lancet Neurol; 2013 Nov; 12(11):1068-75. PubMed ID: 24107292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
    Evans R; Kimura H; Alexander R; Davies CH; Faessel H; Hartman DS; Ishikawa T; Ratti E; Shimizu K; Suzuki M; Tanaka S; Yukitake H; Dauvilliers Y; Mignot E
    Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2207531119. PubMed ID: 35994639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of a Therapeutic Drug for Narcolepsy].
    Irukayama-Tomobe Y; Yanagisawa M
    Brain Nerve; 2018 Nov; 70(11):1255-1263. PubMed ID: 30416119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Criteria for gauging response to sodium oxybate for narcolepsy.
    Steffen AD; Lai C; Weaver TE
    J Sleep Res; 2018 Aug; 27(4):e12628. PubMed ID: 29205601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
    Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
    Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the efficacy of the hypocretin/orexin receptor agonists TAK-925 and ARN-776 in narcoleptic orexin/tTA; TetO-DTA mice.
    Sun Y; Ranjan A; Tisdale R; Ma SC; Park S; Haire M; Heu J; Morairty SR; Wang X; Rosenbaum DM; Williams NS; De Brabander JK; Kilduff TS
    J Sleep Res; 2023 Aug; 32(4):e13839. PubMed ID: 36808670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy.
    Kaushik MK; Aritake K; Imanishi A; Kanbayashi T; Ichikawa T; Shimizu T; Urade Y; Yanagisawa M
    Proc Natl Acad Sci U S A; 2018 Jun; 115(23):6046-6051. PubMed ID: 29784823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
    Thorpy MJ; Shapiro C; Mayer G; Corser BC; Emsellem H; Plazzi G; Chen D; Carter LP; Wang H; Lu Y; Black J; Dauvilliers Y
    Ann Neurol; 2019 Mar; 85(3):359-370. PubMed ID: 30694576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
    Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
    PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy.
    Weinhold SL; Seeck-Hirschner M; Nowak A; Hallschmid M; Göder R; Baier PC
    Behav Brain Res; 2014 Apr; 262():8-13. PubMed ID: 24406723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.
    McClellan KJ; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):311-24. PubMed ID: 27521015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.
    Bogan RK; Thorpy MJ; Dauvilliers Y; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Tang L; Skobieranda F; Šonka K
    Sleep; 2021 Mar; 44(3):. PubMed ID: 33184650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.
    Lecendreux M; Plazzi G; Dauvilliers Y; Rosen CL; Ruoff C; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
    J Clin Sleep Med; 2022 Sep; 18(9):2217-2227. PubMed ID: 35689598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The present and future of synthetic orexin receptor agonists.
    Saitoh T; Sakurai T
    Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.
    Lin JS; Dauvilliers Y; Arnulf I; Bastuji H; Anaclet C; Parmentier R; Kocher L; Yanagisawa M; Lehert P; Ligneau X; Perrin D; Robert P; Roux M; Lecomte JM; Schwartz JC
    Neurobiol Dis; 2008 Apr; 30(1):74-83. PubMed ID: 18295497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
    Bogan RK; Foldvary-Schaefer N; Skowronski R; Chen A; Thorpy MJ
    CNS Drugs; 2023 Apr; 37(4):323-335. PubMed ID: 36947322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial.
    Dauvilliers Y; Roth T; Bogan R; Thorpy MJ; Morse AM; Roy A; Dubow J; Gudeman J
    Sleep; 2023 Nov; 46(11):. PubMed ID: 37246913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
    Malhotra A; Shapiro C; Pepin JL; Hedner J; Ahmed M; Foldvary-Schaefer N; Strollo PJ; Mayer G; Sarmiento K; Baladi M; Chandler P; Lee L; Schwab R
    Sleep; 2020 Feb; 43(2):. PubMed ID: 31691827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy.
    Broughton RJ; Fleming JA; George CF; Hill JD; Kryger MH; Moldofsky H; Montplaisir JY; Morehouse RL; Moscovitch A; Murphy WF
    Neurology; 1997 Aug; 49(2):444-51. PubMed ID: 9270575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.